Novo Nordisk AS (NVO)
120.76
-3.54
(-2.85%)
USD |
NYSE |
Sep 27, 16:00
120.47
-0.29
(-0.24%)
After-Hours: 20:00
Novo Nordisk Research and Development Expense (Annual): 4.710B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.710B |
| December 31, 2022 | 3.409B |
| December 31, 2021 | 2.828B |
| December 31, 2020 | 2.369B |
| December 31, 2019 | 2.132B |
| December 31, 2018 | 2.345B |
| December 31, 2017 | 2.133B |
| December 31, 2016 | 2.165B |
| December 31, 2015 | 2.025B |
| December 31, 2014 | 2.455B |
| December 31, 2013 | 2.089B |
| December 31, 2012 | 1.882B |
| December 31, 2011 | 1.799B |
| December 31, 2010 | 1.709B |
| Date | Value |
|---|---|
| December 31, 2009 | 1.472B |
| December 31, 2008 | 1.551B |
| December 31, 2007 | 1.572B |
| December 31, 2006 | 1.064B |
| December 31, 2005 | 847.61M |
| December 31, 2004 | 733.36M |
| December 31, 2003 | 639.98M |
| December 31, 2002 | 525.98M |
| December 31, 2001 | 475.91M |
| December 31, 2000 | 399.67M |
| December 31, 1999 | 371.10M |
| December 31, 1998 | 396.00M |
| December 31, 1997 | 420.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.132B
Minimum
2019
4.710B
Maximum
2023
3.090B
Average
2.828B
Median
2021
Research and Development Expense (Annual) Benchmarks
| Evaxion Biotech AS | 11.92M |
| Viking Therapeutics Inc | 63.81M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Verona Pharma PLC | 17.22M |
| NuCana PLC | 31.19M |